(Q35777336)

10 August 2017

1 reference

title

Antithrombotic therapy in atrial fibrillation: ximelagatran, an oral direct thrombin inhibitor (English)

1 reference

10 August 2017

1 reference

1

Jonathan L Halperin

1 reference

10 August 2017

publication date

1 March 2004

1 reference

Expert Review of Cardiovascular Therapy

10 August 2017

published in

1 reference

10 August 2017

volume

2

1 reference

10 August 2017

issue

2

1 reference

10 August 2017

page(s)

163-174

1 reference

Prognostic value of plasma von Willebrand factor and soluble P-selectin as indices of endothelial damage and platelet activation in 994 patients with nonvalvular atrial fibrillation

10 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Atrial fibrillation is associated with severe acute ischemic stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Prevalence of five common clinical abnormalities in very elderly people: population based cross sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Increasing trends in hospitalization for atrial fibrillation in the United States, 1985 through 1999: implications for primary prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Interactions of warfarin with drugs and food

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

The frequency and effects of cytochrome P450 (CYP) 2C9 polymorphisms in patients receiving warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Hemorrhagic complications of anticoagulant treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Clinical predictors of prolonged delay in return of the international normalized ratio to within the therapeutic range after excessive anticoagulation with warfarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Why do patients with atrial fibrillation not receive warfarin?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Failure to prescribe warfarin to patients with nonrheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

21 January 2018

New anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Dose-response study of recombinant factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Orally active heparin and low-molecular-weight heparin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Oral direct thrombin inhibitors in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: Rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Effects of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, and dalteparin on the endogenous thrombin potential in venous blood from healthy male subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

No Influence of Ethnic Origin on the Pharmacokinetics and Pharmacodynamics of Melagatran Following Oral Administration of Ximelagatran, a Novel Oral Direct Thrombin Inhibitor, to Healthy Male Volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

No Influence of Obesity on the Pharmacokinetics and Pharmacodynamics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Effects of the oral direct thrombin inhibitor ximelagatran on p-selectin expression and thrombin generation in atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Practical issues in the development of argatroban: a perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Warfarin use among ambulatory patients with nonvalvular atrial fibrillation: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

Guidelines for the management of patients with atrial fibrillation. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines a

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14779072.2.2.163

21 January 2018

Identifiers

DOI

10.1586/14779072.2.2.163

1 reference

10 August 2017

1 reference